Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AMG 102 and erlotinib · 1 trial · 1 indication
Determination of the safety and recommended phase II dose of AMG 102 when combined with erlotinib for the treatment of patients with advanced, previously-treated NSCLC.
Using RECIST v1.1 criteria, DCR was determined by following equation: the number of complete response (CR) participants + the number of partial response (PR) participants + the number of stable disease (SD) participants / the number of complete response (CR) participants + the number of partial response (PR) participants + the number of stable disease (SD) participants + the number of progressive disease (PD) participants.
| Arm | Type | Description |
|---|---|---|
| AMG 102 and erlotinib | EXPERIMENTAL | Combination of AMG 102 and erlotinib |
| Name | Type | Description |
|---|---|---|
| AMG 102 and erlotinib | DRUG | Dose Level -2 Dose level -1 Dose Level 0 AMG 102 5 mg/kg 7.5 mg/kg 15 mg/kg Erlotinib 150 mg 150 mg 150 mg The first cohort of patients in the phase I portion will start at dose level 0 of AMG102. |
Patients must have baseline evaluations performed prior to the first dose of study drug and must meet all inclusion and exclusion criteria. Results of all baseline evaluations, which assure that all inclusion and exclusion criteria have been satisfied, must be reviewed by a Physician Investigator pr...
AMG 102 is an investigational oncology drug being studied for the treatment of cancer, including non-small-cell lung cancer, glioblastoma multiforme, and castrate-resistant prostate cancer. It is a small molecule being developed by Amgen Inc. and is currently in clinical trials.
AMG 102 is being developed by Amgen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AMGN. The drug is an investigational small molecule in the oncology therapeutic area.
AMG 102 is in clinical development, with completed trials in Phase 1 and Phase 2. It is an investigational drug and has not been approved by the FDA. Its development includes studies in various cancer types.
AMG 102 has been studied in several completed clinical trials. NCT00770848 tested it with mitoxantrone and prednisone in castrate-resistant prostate cancer. NCT01113398 evaluated it with Avastin for recurrent malignant glioma. NCT01233687 studied it with erlotinib for advanced non-small-cell lung cancer.
AMG 102 is also known as rilotumumab, a monoclonal antibody targeting hepatocyte growth factor. It has been investigated in oncology clinical trials for various solid tumors, including glioblastoma and non-small-cell lung cancer.